242 related articles for article (PubMed ID: 30168290)
1. Role of donor HLA class I mismatch, KIR-ligand mismatch and HLA:KIR pairings in hematological malignancy relapse after unrelated hematopoietic stem cell transplantation.
Graczyk-Pol E; Rogatko-Koros M; Nestorowicz K; Gwozdowicz S; Mika-Witkowska R; Pawliczak D; Zubala M; Szlendak U; Witkowska A; Tomaszewska A; Nasilowska-Adamska B; Szczepinski A; Wojcik M; Halaburda K; Nowak J
HLA; 2018 Dec; 92 Suppl 2():42-46. PubMed ID: 30168290
[TBL] [Abstract][Full Text] [Related]
2. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
[TBL] [Abstract][Full Text] [Related]
3. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
4. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
5. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
6. Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.
Rogatko-Koroś M; Mika-Witkowska R; Bogunia-Kubik K; Wysoczańska B; Jaskuła E; Kościńska K; Nestorowicz K; Dziopa J; Szlendak U; Gwozdowicz S; Graczyk-Pol E; Lange A; Nowak J
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):63-71. PubMed ID: 27933342
[TBL] [Abstract][Full Text] [Related]
7. Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.
Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Komarnicki M; Gil L; Czyż A; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange AA;
Am J Hematol; 2014 Oct; 89(10):E176-83. PubMed ID: 25044365
[TBL] [Abstract][Full Text] [Related]
8. The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outcome of patients receiving HLA-matched sibling donor hematopoietic stem cell transplantation for myeloid malignancies.
Wang H; He Y; Zhai WJ; Wang M; Zhou Z; Zhao YX; Feng SZ; Han MZ
Swiss Med Wkly; 2013; 143():w13717. PubMed ID: 23299929
[TBL] [Abstract][Full Text] [Related]
9. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893
[TBL] [Abstract][Full Text] [Related]
10. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.
Michaelis SU; Mezger M; Bornhäuser M; Trenschel R; Stuhler G; Federmann B; Oevermann L; Kanz L; Handgretinger R; Bethge WA
Ann Hematol; 2014 Sep; 93(9):1579-86. PubMed ID: 24771045
[TBL] [Abstract][Full Text] [Related]
11. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
12. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.
Farag SS; Bacigalupo A; Eapen M; Hurley C; Dupont B; Caligiuri MA; Boudreau C; Nelson G; Oudshoorn M; van Rood J; Velardi A; Maiers M; Setterholm M; Confer D; Posch PE; Anasetti C; Kamani N; Miller JS; Weisdorf D; Davies SM;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):876-84. PubMed ID: 16864058
[TBL] [Abstract][Full Text] [Related]
13. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
[TBL] [Abstract][Full Text] [Related]
14. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J; Schmoor C; Bethge WA; Ottinger HD; Stelljes M; Zander AR; Volin L; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Bertz H; Grishina O; Socié G;
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1716-26. PubMed ID: 22713691
[TBL] [Abstract][Full Text] [Related]
16. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
17. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
[TBL] [Abstract][Full Text] [Related]
18. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
19. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
[TBL] [Abstract][Full Text] [Related]
20. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation.
Zhao XY; Luo XY; Yu XX; Zhao XS; Han TT; Chang YJ; Huo MR; Xu LP; Zhang XH; Liu KY; Li D; Jiang ZF; Huang XJ
Br J Haematol; 2017 Jun; 177(5):766-781. PubMed ID: 28466469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
